Tranylcypromine

Overview

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).

Indication

用于抑郁症。

Associated Conditions

Depressive Episodes

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
The Effect of Tranexamic Acid in Endoscopic and Microscopic Ear Surgery Cases on Surgeon Satisfaction	2024/05/30	NCT06434636	Not Applicable	Not yet recruiting	TC Erciyes University
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy	2023/11/02	NCT06114758	N/A	Active, not recruiting	Ankara Etlik City Hospital
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)	2016/03/24	NCT02717884	Phase 1	UNKNOWN	Michael Luebbert
Pharmacovigilance in Gerontopsychiatric Patients	2015/03/02	NCT02374567	Phase 3	Terminated	Hannover Medical School
Study of TCP-ATRA for Adult Patients With AML and MDS	2014/10/23	NCT02273102	Phase 1	Completed	University of Miami
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible	2014/10/10	NCT02261779	Phase 1	UNKNOWN	Martin-Luther-Universität Halle-Wittenberg
Interpersonal Psychotherapy for Treatment Resistant Depression	2013/07/11	NCT01896349	Not Applicable	UNKNOWN	Hospital de Clinicas de Porto Alegre
Tranylcypromine Treatment of Bipolar Depression	2011/09/08	NCT01430455	Phase 4	Completed	New York State Psychiatric Institute
PET Biomarkers in Treatment Resistant Depression	2009/12/15	NCT01031810	Phase 4	Terminated	New York State Psychiatric Institute
Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions	2008/04/04	NCT00653393	Phase 1	Completed	Par Pharmaceutical, Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
PARNATE	Concordia Pharmaceuticals Inc.	59212-447	ORAL	10 mg in 1 1	3/1/2021
TRANYLCYPROMINE SULFATE	Par Pharmaceutical, Inc.	49884-032	ORAL	10 mg in 1 1	11/19/2019
Tranylcypromine	Marlex Pharmaceuticals, Inc.	10135-739	ORAL	10 mg in 1 1	3/3/2023
TRANYLCYPROMINE SULFATE	Strides Pharma Science Limited	64380-176	ORAL	10 mg in 1 1	5/26/2023
Tranylcypromine Sulfate	Actavis Pharma, Inc.	0591-5590	ORAL	10 mg in 1 1	3/1/2021
Tranylcypromine	Lannett Company, Inc.	0527-3010	ORAL	10 mg in 1 1	7/7/2022
Tranylcypromine	Solco Healthcare US, LLC	43547-655	ORAL	10 mg in 1 1	7/7/2022
Tranylcypromine	Novitium Pharma LLC	70954-538	ORAL	10 mg in 1 1	6/18/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
TRANYLCYPROMINE ASP tranylcypromine (as sulfate) 10 mg tablet blister pack	387624	MedTAS Pty Ltd	Medicine	A	2/7/2025
TRANAMEF tranylcypromine (as sulfate) 10 mg tablet bottle	444810	Glenmark Pharmaceuticals Australia Pty Ltd	Medicine	A	4/16/2025
TRANYLCYPROMINE NRIM tranylcypromine (as sulphate) 10mg film coated tablet blister pack	224231	Boucher & Muir Pty Ltd	Medicine	A	5/15/2015
PARNATE Tranylcypromine 10mg film coated tablet	174086	Amdipharm Mercury Australia Pty Ltd	Medicine	A	10/21/2010
TRANYLCYPROMINE MEDTAS tranylcypromine (as sulfate) 10 mg tablet blister pack	387623	MedTAS Pty Ltd	Medicine	A	2/7/2025

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access